July 30, 2020 / 6:32 AM / in 10 days

AstraZeneca tops forecasts on strong drug sales, outlook unchanged

July 30 (Reuters) - Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.

Product sales, which exclude payments from tie-ups, rose 9% to $6.05 billion in the three months ended June 30 on a constant-currency basis, surpassing analysts' consensus of $6.01 billion.

Core earnings stood at 96 cents per share versus analysts' estimate of 93 cents. Total revenue rose 11%, AstraZeneca said.

Reporting by Pushkala Aripaka, Ankur Banerjee in Bengaluru and Ludwig Burger in Frankfurt; Editing by Saumyadeb Chakrabarty

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below